Feline Panleukopenie – die wichtige Rolle von Antikörpern

Anna-Lena Proksch; Katherina Mende; Michèle Bergmann; Katrin Hartmann

doi:10.15654/TPK-161024

Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere, Inhaltsverzeichnis

Tierarztl Prax Ausg K Kleintiere Heimtiere 2018; 46(01): 49-56
DOI: 10.15654/TPK-161024

Für Studium und Praxis

Schattauer GmbH

Feline Panleukopenie – die wichtige Rolle von Antikörpern

Feline panleukopenia – the important role of antibodies

Autoren

Anna-Lena Proksch

¹Medizinische Kleintierklinik der Ludwig-Maximilians-Universität München
Katherina Mende

¹Medizinische Kleintierklinik der Ludwig-Maximilians-Universität München
Michèle Bergmann

¹Medizinische Kleintierklinik der Ludwig-Maximilians-Universität München
Katrin Hartmann

¹Medizinische Kleintierklinik der Ludwig-Maximilians-Universität München

Abstract

Zusammenfassung

Die feline Panleukopenie zählt zu den wichtigsten Infektionskrankheiten der Katze. Jede Katze sollte zuverlässig vor Panleukopenie geschützt sein. Eine erfolgreiche Grundimmunisierung ist für die Ausbildung einer belastbaren Immunität essenziell. Panleukopenie tritt nach wie vor häufig auf und betrifft vor allem Katzenwelpen. Maternale Antikörper spielen eine wichtige Rolle für den Schutz der Welpen. Aufgrund ihres langen Fortbestehens, teilweise bis zur 20. Lebenswoche, können maternale Antikörper jedoch mit der Impfung interferieren und den Aufbau einer belastbaren Immunität verhindern. So kannes trotz Impfung zu Erkrankungen kommen. Bei adulten Katzen mit chronischer Krankheit oder Immunsuppression kann die Immunantwort nach einer Impfung reduziert sein. Etwa 30% aller adulten Katzen haben keine Antikörper. Die Bestimmung des Antikörpertiters bei Welpen ermöglicht die Berechnung des optimalen Zeitpunkts für eine erfolgreiche Grundimmunisierung. Bei adulten Tieren bietet die Titerbestimmung eine Alternative, um unnötige Impfungen zu vermeiden und ein individuelles Impfschema zu ermitteln. Nur Katzen ohne Antikörper sollten geimpft werden. Zur Bestimmung des Antikörpertiters steht für die Praxis ein leicht durchführbarer Schnelltest zur Verfügung.

Summary

Feline panleukopenia is an important infectious disease. Despite vaccination, panleukopenia remains common, particularly in young kittens. Development of active immunity after primary vaccination is essential for protection. Therefore, vaccination against panleukopenia is a core vaccine. Efficacy of primary vaccination can be reduced by maternally derived antibodies that can persist up to 20 weeks and interfere with the vaccination. In adult cats, antibody development after vaccination can be reduced during chronic disease or immunosuppression. Approximately 30% of adult cats lack antibodies. Evaluation of antibody titres in kittens enables calculation of the ideal time point to initiate primary vaccinations with the goal to establish effective immunity. In adult cats, evaluation of antibody titres is a useful alternative to avoid unnecessary vaccinations and to create an individual vaccination schedule. Only cats lacking antibodies should be vaccinated. Evaluation of antibodies in private practice can be performed using a rapid in-house test.

SchlüsselWörter

Katze - felines Parvovirus - Impfung - Schnelltest - Hämmagglutinations-hemmtest - ELISA - Titer

Keywords

Cat - feline parvovirus - vaccination - rapid in-house test - haemagglutination inhibition - ELISA - titre

Volltext

Referenzen

Literatur
1 Bergmann M, Friedl Y, Hartmann K. Passive Immunisierung bei Hund und Katze. Tierärztl Prax 2016; 44 (K): 287-292.
2 Blanco K, Prendas J, Cortes R, Jimenez C, Dolz G. Seroprevalence of viral infections in domestic cats in Costa Rica. J Vet Med Sci 2009; 71: 661-663.
3 Brun A, Chappuis G, Precausta P, Terre J. Immunisation against panleu-kopenia: early development of immunity. Comp Immunol Microbiol Infect Dis 1979; 01: 335-339.
4 Casseleux G, Fontaine E. Gestion de la parvovirose en elevage canin. Point Veterinaire 2006; 37: 42-46.
5 Chalmers WS, Truyen U, Greenwood NM, Baxendale W. Efficacy of feline panleucopenia vaccine to prevent infection with an isolate of CPV2b obtained from a cat. Vet Microbiol 1999; 69: 41-45.
6 Claus MA, Levy JK, MacDonald K, Tucker SJ, Crawford PC. Immunoglobulin concentrations in feline colostrum and milk, and the requirement of colostrum for passive transfer of immunity to neonatal kittens. J Feline Med Surg 2006; 08: 184-191.
7 Dawson S, Willoughby K, Gaskell RM, Wood G, Chalmers WS. A field trial to assess the effect of vaccination against feline herpesvirus, feline calicivirus and feline panleucopenia virus in 6-week-old kittens. J Feline Med Surg 2001; 03: 17-22.
8 Day M. What we need to know about vaccination and titre testing. British Small Animal Veterinary Association Congress 2012, Birmingham..
9 Day M. Utility of serum antibody assays to monitor protection and the need for vaccination. Pre-Congress Symposium, European College of Veterinary Internal Medicine 2013, Liverpool..
10 Day MJ, Schoon HA, Magnol JP, Saik J, Devauchelle P, Truyen U, Gruffydd-Jones TJ, Cozette V, Jas D, Poulet H, Pollmeier M, Thibault JC. A kinetic study of histopathological changes in the subcutis of cats injected with non-adjuvanted and adjuvanted multi-component vaccines. Vaccine 2007; 25: 4073-4084.
11 Day MJ, Horzinek MC, Schultz RD. WSAVA guidelines for the vaccination of dogs and cats. J Small Anim Pract 2010; 51: 1-32.
12 Digangi BA, Levy JK, Griffin B, Reese MJ, Dingman PA, Tucker SJ, Dubovi EJ. Effects of maternally-derived antibodies on serologic responses to vaccination in kittens. J Feline Med Surg 2012; 14: 118-123.
13 DiGangi BA, Gray LK, Levy JK, Dubovi EJ, Tucker SJ. Detection of protective antibody titers against feline panleukopenia virus, feline herpesvirus-1, and feline calicivirus in shelter cats using a point-of-care ELISA. J Feline Med Surg 2011; 13: 912-918.
14 Erhardt W. [Use of passive and active vaccines against panleukopenia in cats]. Berl Munch Tierarztl Wochenschr 1977; 90: 337-340.
15 Franchini M. Die Tollwutimpfung von mit felinem Leukämievirus infi-zierten Katzen. Dissertation, Universität Zürich. 1990
16 Friedrich K, Truyen U. Untersuchungen der Wirksamkeit von Parvovirus -impfstoffen und der Effektivitäg zweier Impfschemata. Prakt Tierarzt 2000; 12: 988-994.
17 Gamoh K, Senda M, Inoue Y, Itoh O. Efficacy of an inactivated feline pan-leucopenia virus vaccine against a canine parvovirus isolated from a domestic cat. Vet Rec 2005; 157: 285-287.
18 Gerlach M, Proksch AL, Unterer S, Speck S, Truyen U, Hartmann K. Efficacy of feline anti-parvovirus antibodies in the treatment of canine parvovirus infection. J Small Anim Pract 2017; 58 (07) 408-415.
19 Gore TC, Lakshmanan N, Williams JR, Jirjis FF, Chester ST, Duncan KL, Coyne MJ, Lum MA, Sterner FJ. Three-year duration of immunity in cats following vaccination against feline rhinotracheitis virus, feline calicivirus, and feline panleukopenia virus. Vet Ther 2006; 07: 213-222.
20 Greene C. ed. Feline parvovirus infection. In: Infectious Diseases of the Dog and the Cat. Philadelphia: Saunders; 2012: 80-88.
21 Greene CE, Levy JK. Immunoprophylaxis. In: Infectious Diseases of the Dog and Cat. 4th edn.. Greene CE. ed. St. Louis, MO: Elsevier Saunders; 2012: 1163-1205.
22 Greene CE, Addie DD. Feline parvovirus infection. In: Infectious Diseases of the Dog and Cat. Greene CE. ed. Philadelphia: Saunders; 2006: 80-88.
23 Hanson BJ, Boon AC, Lim AP, Webb A, Ooi EE, Webby RJ. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 2006; 07: 126.
24 Hartmann K, Day MJ, Thiry E, Lloret A, Frymus T, Addie D, Boucraut-Baralon C, Egberink H, Gruffydd-Jones T, Horzinek MC, Hosie MJ, Lutz H, Marsilio F, Pennisi MG, Radford AD, Truyen U, Mostl K. Feline injection-site sarcoma: ABCD guidelines on prevention and management. J Feline Med Surg 2015; 17: 606-613.
25 Hartmann K, Kohn B, Moritz A, Schulte K, Steidl T, Straubinger R, Truyen U. Ständige Impfkommision Veterinär (StiKo Vet). Leitlinie zur Impfung von Kleintieren. 2017
26 Hellard E, Fouchet D, Santin-Janin H, Tarin B, Badol V, Coupier C, Leblanc G, Poulet H, Pontier D. When cats’ ways of life interact with their viruses: a study in 15 natural populations of owned and unowned cats (Felis silvestris catus). Prev Vet Med 2011; 101: 250-264.
27 Hoffmann A, Schönborn E, Mergel A, Cußler K. Pharmakovigilanzreport Tierimpfstoffe, Analyse der im Jahr 2008 und 2009 im Paul-Ehrlich-Institut eingegangenen Meldungen. Deutsches Tierärzteblatt 2010; 06: 766-775.
28 Horzinek MC, Thiry E. Vaccines and vaccination: the principles and the polemics. J Feline Med Surg 2009; 11: 530-537.
29 Jakel V, Cussler K, Hanschmann KM, Truyen U, König M, Kamphuis E, Duchow K. Vaccination against Feline Panleukopenia: Implications from a field study in kittens. BMC Vet Res 2012; 08: 62.
30 Jas D, Aeberlé C, Lacombe V, Guiot AL, Poulet H. Onset of immunity in kittens after vaccination with a non-adjuvanted vaccine against feline pan-leucopenia, feline calicivirus and feline herpesvirus. Vet J 2009; 182: 86-93.
31 Kruse BD, Unterer S, Horlacher K, Sauter-Louis C, Hartmann K. Prognostic factors in cats with feline panleukopenia. J Vet Intern Med 2010; 24: 1271-1276.
32 Kruse BD, Unterer S, Horlacher K, Sauter-Louis C, Hartmann K. Feline Panleukopenie – differierender Krankheitsverlauf bei Katzen im Alter von unter bzw. über 6 Monaten?. Tierärztl Prax 2011; 39 (K): 237-242.
33 Lappin MR, Andrews J, Simpson D, Jensen WA. Use of serologic tests to predict resistance to feline herpesvirus 1, feline calicivirus, and feline parvovirus infection in cats. J Am Vet Med Assoc 2002; 220: 38-42.
34 Lappin MR. Feline panleukopenia virus, feline herpesvirus-1 and feline cali civirus antibody responses in seronegative specific pathogen-free kittens after parenteral administration of an inactivated FVRCP vaccine or a mo -dified live FVRCP vaccine. J Feline Med Surg 2012; 14: 161-164.
35 Levy JK, Crawford PC, Lappin MR, Dubovi EJ, Levy MG, Alleman R, Tucker SJ, Clifford EL. Infectious diseases of dogs and cats on Isabela Island, Galapagos. J Vet Intern Med 2008; 22: 60-65.
36 Luff PR, Wood GW, Hebert CN, Thornton DH. Canine parvovirus serology: a collaborative assay. Vet Rec 1987; 120: 270-273.
37 Macartney L, Thompson H, McCandlish IA, Cornwell HJ. Canine parvovirus: interaction between passive immunity and virulent challenge. Vet Rec 1988; 122: 573-576.
38 Mende K, Stuetzer B, Truyen U, Hartmann K. Evaluation of an in-house dot enzyme-linked immunosorbent assay to detect antibodies against feline panleukopenia virus. J Feline Med Surg 2014; 16: 805-811.
39 Mende K, Stuetzer B, Sauter-Louis C, Homeier T, Truyen U, Hartmann K. Prevalence of antibodies against feline panleukopenia virus in client-owned cats in Southern Germany. Vet J 2014; 199: 419-423.
40 Modrow S, Falke D, Truyen U, Schaetzl H. Molekulare Virologie. Heidelberg: Spektrum Akademischer Verlag 2010
41 Mouzin DE, Lorenzen MJ, Haworth JD, King VL. Duration of serologic response to three viral antigens in cats. J Am Vet Med Assoc 2004; 224: 61-66.
42 Patterson EV, Reese MJ, Tucker SJ, Dubovi EJ, Crawford PC, Levy JK. Effect of vaccination on parvovirus antigen testing in kittens. J Am Vet Med Assoc 2007; 230: 359-363.
43 Pollock RVH, Postorino NC. Feline panleukopenia and other enteric viral diseases. In: The Cat: Diseases and Clinical Management. Sherding RG. ed. New York: Churchill Livingstone; 1994: 479-487.
44 Poulet H. Alternative early life vaccination programs for companion animals. J Comp Pathol 2007; 137 (Suppl. 01) S67-71.
45 Reese MJ, Patterson EV, Tucker SJ, Dubovi EJ, Davis RD, Crawford PC, Levy JK. Effects of anesthesia and surgery on serologic responses to vaccination in kittens. J Am Vet Med Assoc 2008; 233: 116-121.
46 Scherk MA, Ford RB, Gaskell RM, Hartmann K, Hurley KF, Lappin MR, Levy JK, Little SE, Nordone SK, Sparkes AH. 2013 AAFP Feline Vaccination Advisory Panel Report. J Feline Med Surg 2013; 15: 785-808.
47 Scott FW, Csiza CK, Gillespie JH. Feline viruses. V. Serumneutralization test for feline panleukopenia. Cornell Vet 1970; 60: 183-191.
48 Scott FW, Csiza CK, Gillespie JH. Maternally derived immunity to feline panleukopenia. J Am Vet Med Assoc 1970; 156: 439-453.
49 Scott FW, Geissinger CM. Long-term immunity in cats vaccinated with an inactivated trivalent vaccine. Am J Vet Res 1999; 60: 652-658.
50 Srivastav A, Kass PH, McGill LD, Farver TB, Kent MS. Comparative vaccine-specific and other injectable-specific risks of injection-site sarcomas in cats. J Am Vet Med Assoc 2012; 241: 595-602.
51 Tizard I, Ni Y. Use of serologic testing to assess immune status of companion animals. J Am Vet Med Assoc 1998; 213: 54-60.
52 Tizard IR. ed. B cells and their response to antigen. In: Veterinary Immunology. Philadelphia: Saunders; 2012: 150-164.
53 Tizard IR. ed. Helper T cells and their response to antigen. In: Veterinary Immunology. Philadelphia: Saunders; 2012: 137-149.
54 Tizard IR. ed. Immunity in the fetus and newborn. In: Veterinary Immunology. Philadelphia: Saunders; 2012: 225-239.
55 Tizard IR. ed. Vaccines and their production. In: Veterinary Immunology. Philadelphia: Saunders; 2012: 258-271.
56 Truyen U, Addie D, Belak S, Boucraut-Baralon C, Egberink H, Frymus T, Gruffydd-Jones T, Hartmann K, Hosie MJ, Lloret A, Lutz H, Marsilio F, Pennisi MG, Radford AD, Thiry E, Horzinek MC. Feline panleukopenia. ABCD guidelines on prevention and management. J Feline Med Surg 2009; 01: 538-546.
57 Waner T, Naveh A, Wudovsky I, Carmichael LE. Assessment of maternal antibody decay and response to canine parvovirus vaccination using a clinic-based enzyme-linked immunosorbent assay. J Vet Diagn Invest 1996; 08: 427-432.
58 Waner T, Mazar S, Keren-Kornblatt E. Application of a dot enzyme-linked immunosorbent assay for evaluation of the immune status to canine parvovirus and distemper virus in adult dogs before revaccination. J Vet Diagn Invest 2006; 18: 267-270.